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patients receiving coronary artery stents in a managed
care population. METHODS: Patients were selected
from the PharMetrics Integrated Outcomes Database
who underwent coronary angioplasty and stent insertion
between January 1 and June 30, 1999 and who had at
least 6 months of continuous enrollment in their health
plan following the beginning of the treatment episode.
Patients were grouped according to whether they received
outpatient anticoagulant/antiplatelet prescription drug
therapy following their stent procedure. Patients were
also stratified by history of acute myocardial infarction
(AMI) and presence of comorbid conditions (diabetes
and hypertension). Total charges associated with the
stenting treatment episode (up to 6 months following the
procedure) were assessed. RESULTS: 2,713 patients re-
ceiving anticoagulant/antiplatelet therapy and 438 un-
treated patients met all selection criteria. The two treat-
ment groups were similar in age (58.6 vs. 58.0 years
respectively, p  0.322) and in the frequency of AMI
(37.7% vs. 37.9% respectively, p  0.939) and of one or
more comorbidities (73.3% vs. 71.5% respectively, p 
0.427). Mean charges over the study period for the anti-
coagulant/antiplatelet cohort exceeded those in the un-
treated cohort by $4,748 (p  0.014). Pharmacy charges
accounted for only $297 of this excess ($660 vs. $363,
respectively). Most of the difference between treatment
groups was in the medical costs of interventional cardiol-
ogy. CONCLUSION: Among coronary stent recipients,
the mean charge for a 6-month period in patients who
also received anticoagulant/antiplatelet prescription drug
therapy was 14% higher than in the untreated cohort,
due mainly to higher medical charges. It is possible that
untreated patients were less severely ill or had a favorable
risk profile. Further investigation of these data will exam-
ine this issue.
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OBJECTIVE: To estimate the cost-effectiveness of enox-
aparin (1 mg/kg s.c. bid) vs unfractionated heparin
(UFH) (i.v. bolus and constant infusion adjusted to main-
tain a therapeutic APTT) in acute coronary syndrome
(ACS) patients from a Polish hospital perspective. The in-
tention was to facilitate the decision-making process in
selecting the most cost-effective treatment for ACS.
METHODS: Decision model was used to quantify costs
and effectiveness of alternative treatments. Published re-
sults from ESSENCE study were used to estimate the
probability for clinical end-points (death, MI, recurrent
angina) at 30 days. Probabilities of patients receiving
revascularisation procedures were obtained from the
GRACE registry (961 patients at 6 centres in Poland).
The analysis assessed only direct medical costs resulting
from the treatment of events comprising the composite
end-point, revascularisation procedures, enoxaparin and
UFH therapy, related medications. The costs were deter-
mined from actual resource consumption on a patient-
specific basis (6 months observational study) and esti-
mated using Polish data on unit costs. One- and two-way
sensitivity analysis and treshold analysis were performed.
RESULTS: At 30 days 19,8% of patients receiving enox-
aparin compared with 23,3% of patients receiving UFH
reached one event of the composite end-point (p  0,02).
The average costs (in PLN, 1 USD  4 PLN) were 1085
per patient receiving enoxaparin compared with 1097 per
patient receiving UFH. Therefore for every 29 patients
treated, enoxaparin therapy would not only avoid one
event of the composite end-point, it would also save 348
PLN. The threshold analysis revealed, that enoxaparin
would lose the dominance, when cost of enoxaparin ther-
apy would increase by 30%, cost of UFH—decrease by
47%, probability end-point in enoxaparin arm increase
to 0.22 or in UFH arm decrease to 0.2. CONCLUSION:
Since enoxaparin resulted in a better effect at a lower
cost, this antithrombotic strategy was considered to be
dominant for Polish patients with ACS.
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OBJECTIVE: The objective of this study was to examine
the role of quality of life (QOL) and patient preference as
predictors for resource utilization among patients with
heart failure (HF). METHODS: QOL, patient preference,
resource utilization, and survival are being assessed in 94
patients with HF managed in an urban HF specialty
clinic. QOL is measured using a disease-specific question-
naire, the Kansas City Cardiomyopathy Questionnaire
(KCCQ) and a generic questionnaire, the Short Form 12
(SF-12), at baseline, 3 months, and 6 months. Patient
preference is measured using standard gamble technique
at baseline. Resource use including hospitalization, ER
visits, procedures, and outpatient visits are captured by
patient interview and verified by clinic and hospital
records. Health care costs are derived from clinic cost
data, University Health System Consortium database,
and literature. RESULTS: To date, 81 patients have com-
pleted 3 months follow-up (mean age 49.9  14.0 years;
69% African American; 53% male; NYHA class I  15,
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II  24, III  38; mean left ventricular ejection fraction 
34.3%  15.5). Mean disease-specific QOL (KCCQ
Overall Summary Score  66.9) and generic QOL (Phys-
ical Component Summary  38.7; Mental Component
Summary  48.2) were similar to literature values for HF
patients. Mean utility was 0.832. Using linear regression,
lower KCCQ scores, SF-12 scores, and utility at baseline
were all significantly associated with higher resource uti-
lization at 3 months. When patients were grouped into
three categories based on their baseline KCCQ Overall
Summary Score (I  0–50, II  50 to £75, III  75),
resource utilization over 3 months was significantly dif-
ferent across the groups (I  $4033; II  $2500; III 
$2010; p  0.0003). CONCLUSION: Among patients
with HF, QOL and patient preference appear to predict
future resource utilization.
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Risk equations based on the Framingham Heart Study
(FHS) are used in NZ to predict the 5y risk of incident
cardiovascular (CV) events. OBJECTIVE: To establish
how well the FHS equations predict first hospitalisation
or mortality from CV events in a New Zealand (NZ)
population without overt CV disease. METHODS: Ob-
servations were taken from a cohort study with 6354
(4638 M 1716 F) participants age 32–74 without
known CV disease, taken from the workforce of a na-
tion-wide multi-industry corporation plus a random sam-
ple of the Auckland electoral rolls. Prognostic factors
were assessed in 1992/93 by a questionnaire plus physio-
logical measurements (BP, cholesterol etc.). Age-specific
risk predictions from the FHS were compared with age-
specific mortality plus relevant hospital discharges from
January 1988 to December 1998 (NZ Health Informa-
tion Service). RESULTS: The 5y incidence of first hospi-
talisation for any CV event was 6.4% (male) and 4.4%
(female). Table 1 compares observed hospitalised events
or mortality with predicted incident events, averaged
across 5y age bands.
CONCLUSIONS: FHS risk equations accurately predict
age-specific incident hospitalized CHD or stroke events
or mortality for NZ males age 30–74 but under-estimate
MI events. Prediction is less accurate and precise for fe-
males.
Ratio of observed to predicted events, averaged across 8 	 
5y age bands
Mean ratio (SD) Male Female Both
CHD 1.03  0.15 0.92  0.35 1.03  0.06
MI 1.24  0.19 1.49  1.19 1.26  0.15
STROKE 0.98  0.40 0.74  0.57 0.94  0.42
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Risk equations based on the Framingham Heart Study
(FHS) are used in NZ to predict the 5y risk of an incident
CV event for individuals without cardiovascular (CV)
disease. OBJECTIVES: To establish in a NZ population
without overt CV disease: (i) the discriminability of the
relevant FHS risk equation for prediction of first hospi-
talisation or mortality for any cardiovascular event; (ii)
whether FHS risk equations have better discriminability
than single risk factors. METHODS: Observations were
taken from a cohort study with 6354 (4638 M  1716 F)
participants age 32–74 without known CV disease, taken
from the workforce of a nation-wide multi-industry cor-
poration plus a random sample of the Auckland electoral
rolls. Prognostic factors were assessed in 1992–93 by a
questionnaire plus physiological measurements (BP, cho-
lesterol etc.). Outcomes data were CV mortality and hos-
pital discharges from Jan. 1988 to Dec. 1998 (NZ Health
Information Service). Risk predictions were compared
with outcomes, and receiver-operator characteristics
(ROC) curves were constructed. The area under the ROC
curve was obtained by fitting a dual-Gaussian unequal
variance model. RESULTS: Table 1 shows the area under
the ROC curves.
CONCLUSIONS: FHS risk equations or age alone pro-
vide moderate discriminability for individuals with 5y
risk of a CV event that requires hospitalisation. SBP and
serum lipids have weaker discriminability.
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OBJECTIVES: Economic studies on the cost of DVT usu-
ally take into account the acute care costs only although
the patients are treated and followed-up after hospital
discharge for at least six months. We calculated the true
economic burden of the disease. METHODS: We as-
sessed from the Health Care System perspective the total
cost of managing a patient with DVT over a one-year
Area under ROC curves (95% CI).
Male Female Total
FHS .72  .030 .78  .055 .74  .025
Age .70  .029 .77  .058 .71  .026
SBP .62  .034 .69  .062 .64  .030
Chol/HDLc .61  .034 .64  .066 .63  .030
BMI .56  .034 .61  .063 .58  .029
